Category: Top Story

MONY Group (LSE:MONY) reported record financial results for 2025, with revenue rising to £446.3 million and adjusted EBITDA reaching an all-time high of £145.1 million, both up 2% year on year despite ongoing pressure in the car insurance market. Operating costs declined by 4%, helping lift the EBITDA margin to 33%. Performance was supported by strong growth in the Money and Home Services divisions, while Travel and Cashback segments delivered weaker contributions. The company estimates it enabled UK households to save £2.8 billion during the year and close to £12 billion over the past five years.

The group returned £96 million to shareholders through dividends and a completed £30 million share buyback, increased the total dividend to 12.63p per share, and announced an additional £25 million buyback programme, reflecting confidence in ongoing cash generation. Strategic priorities include expanding its SuperSaveClub membership platform, which now exceeds 2.1 million members and contributes around 16% of group revenue, alongside strengthening services for providers and accelerating artificial intelligence adoption. Initiatives include an enterprise agreement with OpenAI, the launch of products such as Savings by MoneySuperMarket and Price Optimiser, and the introduction of a MoneySuperMarket ChatGPT application. The board expects 2026 adjusted EBITDA to align with current market consensus forecasts.

MONY Group’s outlook is supported by strong financial performance, attractive valuation metrics and continued shareholder returns through buybacks. However, technical indicators suggest some bearish momentum in the near term, which could introduce short-term volatility. Strong cash flow generation and disciplined debt management nevertheless provide a solid platform for longer-term growth.

More about MONY Group PLC

MONY Group PLC, owner of MoneySuperMarket, operates a UK-based consumer finance and price comparison platform connecting households with products across insurance, personal finance, home services, travel and cashback markets. The company uses data analytics and AI-enabled technology to power a two-sided marketplace serving both consumers and product providers.

United Oil & Gas (LSE:UOG) has completed the second phase of its Surface Geochemical Exploration campaign and has now moved into the crucial third stage involving piston coring activities on the Walton Morant licence offshore Jamaica. Operations are primarily focused within the Walton Basin, close to the Colibri, Streamertail and Oriole prospects, while additional sampling sites in the Morant Basin have been selected using integrated multibeam and seismic datasets.

The company plans to recover up to 42 seabed core samples over approximately one week. These samples will be analysed at specialist laboratories in Houston to identify thermogenic hydrocarbons, which would provide direct evidence of an active petroleum system. The programme represents an important step toward reducing exploration risk across the Jamaican acreage, improving subsurface interpretation and supporting ongoing technical assessments and potential commercial or partnership discussions linked to future exploration plans.

United Oil & Gas’s outlook continues to be constrained by weak financial fundamentals, including the absence of revenue, ongoing losses and uneven cash generation, although relatively low leverage offers some balance-sheet support. Technical indicators remain a notable positive, pointing to an established upward trend with solid momentum. However, valuation metrics remain challenged due to negative earnings and the lack of a meaningful price-to-earnings benchmark.

More about United Oil & Gas Plc

United Oil & Gas Plc is an AIM-listed independent oil and gas company focused on high-impact exploration and development opportunities. Its portfolio includes an offshore exploration licence in Jamaica alongside a UK development asset. Supported by an experienced management team, the company aims to create value through exploration success, portfolio optimisation and selective acquisitions alongside established industry partners.

Diageo plc (LSE:DGE) Chief Executive Sir Dave Lewis is reportedly lining up a far-reaching reshuffle of the group’s senior leadership as part of efforts to tackle internal cultural challenges, according to sources cited by the Financial Times.

The report, referencing individuals familiar with the matter, says Lewis intends to replace several members of Diageo’s 14-strong executive committee. The move would form part of a broader transformation plan at the London-based drinks giant, which owns global brands including Johnnie Walker whisky, Captain Morgan rum and Guinness.

One source described the proposed reforms as sweeping in scope, suggesting the new CEO is considering substantial structural changes. The same individual indicated that decision-making within the company had become overly complex and that a degree of complacency had set in across parts of the organisation, which employs more than 29,000 people worldwide.

Although no formal announcements are expected at next week’s interim results, investors are said to be anticipating decisive steps as part of a wider turnaround strategy. Another person familiar with Lewis’s approach suggested that the overhaul could involve eliminating entire layers of management in an effort to streamline operations and improve accountability.

Tullow Oil (LSE:TLW) has reached agreement on a wide-ranging refinancing with approximately two-thirds of its senior secured noteholders and Glencore, reshaping its debt profile and extending maturities. The transaction replaces the company’s 2026 senior secured notes with new “Extended Notes” due in November 2028, alongside new junior notes issued to Glencore maturing in 2030.

The restructuring reduces near-term refinancing pressure, lowers overall cash interest costs and avoids equity dilution. It also introduces enhanced creditor oversight, including the appointment of at least three new independent non-executive directors and the creation of a dedicated value maximisation committee at board level.

As part of the package, $1.285 billion of existing senior secured notes and Glencore’s $400 million facility will be written down and exchanged. The agreement also includes a mandatory repayment of at least $100 million on the new notes and establishes a new $100 million super senior cargo prepayment facility secured against Ghanaian oil cargoes.

By extending its debt maturities and stabilising its capital structure, Tullow aims to create financial flexibility to deliver its 2026–2027 investment plans in Ghana. Priorities include securing licence extensions, addressing outstanding tax and receivable matters with the government, and advancing drilling programmes, gas monetisation projects and potential FPSO ownership initiatives. Management believes these steps could support long-term production stability and value creation for both creditors and shareholders.

From an investment perspective, the company continues to face material balance sheet risks, including negative equity and elevated leverage, despite solid operating cash generation. Technical indicators show improving short-term momentum, though the broader long-term trend remains fragile. Valuation metrics offer limited comfort, with a negative price-to-earnings ratio and no dividend yield currently in place.

More about Tullow Oil

Tullow Oil plc is an independent upstream oil and gas company with its core producing assets in Ghana’s Jubilee and TEN fields. Listed in London and Ghana, the group focuses on exploration and production across West Africa, monetising crude oil and gas through established offtake and infrastructure arrangements while pursuing cost efficiencies and production optimisation to enhance reserves and cash flow generation.

Aston Martin Lagonda (LSE:AML) has reached an agreement in principle to sell the perpetual rights to use the Aston Martin name and chassis designation for the Aston Martin Formula 1 Team to AMR GP Holdings for £50 million. The transaction also covers certain F1-related branding rights.

Because Executive Chairman Lawrence Stroll is connected to AMR GP, the deal qualifies as a substantial property transaction and related-party arrangement under UK Listing Rules. Shareholder approval is required, although backing is effectively assured, with investors representing 54.27% of the issued share capital already committed to vote in favour.

Alongside the announcement, the company provided a trading update for 2025. Wholesale volumes totalled 5,448 vehicles, down from 6,030 the previous year, reflecting fewer high-margin special models and the impact of U.S. tariffs. Adjusted EBIT is expected to land slightly below the lower end of analyst forecasts.

Cost-reduction initiatives have helped lower operating expenses and capital expenditure, while liquidity remained broadly stable at £250 million. Management anticipates that proceeds from the naming-rights sale, combined with a stronger product mix — including around 500 deliveries of the Valhalla — will support a meaningful financial recovery in 2026.

The company’s independent directors, advised by Goldman Sachs International, have concluded that the terms of the transaction are fair and reasonable for shareholders. Strategically, the move unlocks value from Aston Martin’s Formula 1 association while maintaining its longer-term sponsorship presence, potentially reinforcing the balance sheet as the group continues its transformation programme and expands its model portfolio in a challenging luxury automotive market.

From an investment standpoint, the outlook remains constrained by elevated leverage and ongoing losses. While short-term technical indicators show signs of recovery, the longer-term trend is still fragile. Valuation metrics are pressured by negative earnings, and macroeconomic headwinds continue to pose risks despite management’s efforts to stabilise operations and reposition the brand.

More about Aston Martin Lagonda Global Holdings plc

Aston Martin Lagonda is a British ultra-luxury performance car manufacturer headquartered in Gaydon, England. The company produces high-end sports cars and SUVs — including the Vantage, DB12, Vanquish, DBX and Valhalla — blending advanced engineering with traditional craftsmanship. Its vehicles are sold in more than 50 countries worldwide, with SUV production based in St Athan, Wales.

AstraZeneca (LSE:AZN) has received approval from the U.S. Food and Drug Administration for Calquence (acalabrutinib) in combination with venetoclax as the first fully oral, fixed-duration treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The 14-month regimen offers a defined course of therapy, providing an alternative to indefinite treatment and enabling clinicians to tailor care to individual patient preferences and clinical needs.

The decision is supported by data from the Phase III AMPLIFY trial, in which the Calquence–venetoclax combination demonstrated a statistically significant improvement in progression-free survival compared with standard chemoimmunotherapy. At the three-year mark, 77% of patients receiving the combination remained progression-free, versus 67% in the chemotherapy arm. The safety profile was consistent with prior experience of Calquence. The regimen has already been authorised in Europe, Canada, the U.K. and other markets, reinforcing AstraZeneca’s position in the first-line CLL setting.

Beyond CLL, the company continues to evaluate Calquence both as monotherapy and in combination regimens across a range of B-cell malignancies, including mantle cell lymphoma and diffuse large B-cell lymphoma. The expanded U.S. label, alongside ongoing global regulatory activity, supports AstraZeneca’s ambition to strengthen its haematology franchise and broaden adoption of its BTK inhibitor-based therapies in a sizable and growing patient population.

From an investment perspective, the company’s outlook remains underpinned by solid operational performance, earnings growth guidance and continued pipeline advancement. However, valuation metrics — including a price-to-earnings ratio around 30 — and variability in recent free cash flow temper the picture. Technical indicators suggest the shares remain in an overall uptrend, though momentum appears somewhat stretched.

More about AstraZeneca

AstraZeneca is a global, science-driven biopharmaceutical group headquartered in Cambridge, U.K. The company focuses on developing and commercialising prescription medicines across oncology, rare diseases and biopharmaceuticals, spanning cardiovascular, renal and metabolism, as well as respiratory and immunology. Its oncology and haematology portfolio has been strengthened through acquisitions including Alexion and Gracell Biotechnologies, with medicines marketed in more than 125 countries worldwide.